AbbVie Inc. (ABBV) — closed signal from October 21, 2025
Partial Published before the outcome was known, scored automatically when the window closed on January 19, 2026.
Predicted vs. what happened
What happened
Reached 29% of the predicted growth at its peak, without hitting the target.
The thesis — published October 21, 2025
AbbVie's price looks beaten down in the short term, while overall investor mood remains upbeat. A recent study showed Rinvoq outperforming Humira, which supports the view that future sales can keep growing. The company's long history of paying and raising dividends adds a cushion. Short-term trend signs look weak, so we prefer a moderate position and look for the price to steady over the next 0-3 months.
Primary drivers
- Rinvoq topped Humira in a study, boosting confidence in future sales.
- Long record of rising dividends keeps many investors confident and engaged.
- Short-term signals look weak after a drop, so timing entries carefully matters.
- Strong overall mood, but keep position size modest to handle price swings.
How it played out
ABBV: target missed after a small early rise
Lyra published ABBV at $231.21 on 2025-10-21 with a short-term view for 12% growth. The thesis pointed to Rinvoq topping Humira in a study, a long record of rising dividends, weak short-term signals after a drop, and upbeat overall investor mood. It also called for moderate sizing over the next 0-3 months.
Inside the window, ABBV peaked at $239.29 on 2025-11-13, a 3.5% gain. It stayed below the $258.96 target. It never got there. By 2026-01-19, the stock ended at $214.35. The thesis only partially played out, because the price rose briefly but missed the target and finished below publication price.
What happened during the window
On 2025-10-31, AbbVie reported third-quarter results with $15.78 billion in revenue and adjusted earnings of $1.86 per share. On 2026-01-13, The Wall Street Journal reported that AbbVie struck a deal to invest $100 billion in U.S. operations and lower Medicaid prices.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.